Skip to content

Extended Reality (XR)-Assisted CT Localization of Pulmonary Nodules

Extended Reality (XR)-Assisted CT Localization of Pulmonary Nodules

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07434167
Enrollment
30
Registered
2026-02-25
Start date
2026-03-01
Completion date
2026-12-01
Last updated
2026-02-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Extended Reality (XR), Lung Cancers, Metaverse

Keywords

Metaverse, Extended Reality (XR), Digital Twin, Localization of Pulmonary Nodules, uniportal VATS

Brief summary

Extended Reality (XR)-Assisted CT Localization of Pulmonary Nodules

Detailed description

The objective of this study is to investigate the safety and feasibility of extended reality (XR)-assisted computed tomography (CT)-guided localization of pulmonary nodules for preoperative tumor localization. The study aims to utilize a fully developed XR system to assist physicians in performing preoperative localization of pulmonary tumors, while also optimizing the workflow and efficiency of pulmonary nodule localization in a conventional CT suite. This study plans to enroll 30 patients at our institution who are scheduled to undergo thoracoscopic sublobar resection. The safety and feasibility of using an XR-assisted digital twin model for pulmonary nodule localization in a standard CT suite will be evaluated.

Interventions

PROCEDUREExtended Reality (XR)-Assisted CT Localization of Pulmonary Nodules

This study plans to collect approximately 30 localization cases from multiple centers within our institution. First, after patient positioning and immobilization in the computed tomography (CT) suite, a chest CT scan is performed. Imaging data are processed using semi-automatic segmentation and rapid reconstruction techniques to generate, in real time, a three-dimensional model that corresponds to the patient's current localization position. During the construction of the three-dimensional model, patients remain in a fixed position. To reduce anxiety and discomfort associated with waiting, patient education related to pulmonary nodule localization and thoracoscopic surgery is provided during this period. The educational content includes the purpose of the procedure, procedural steps, potential risks, and key points of postoperative care. Once model construction is completed, a metaverse-based XR platform is used in the same setting to overlay the digital twin model onto the patient's

Sponsors

National Taiwan University Hospital
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Patients aged between 18 and 80 who are scheduled to undergo lung nodule resection surgery. * Patients with lung nodules smaller than 2 cm that require preoperative localization. * Patients with lung nodules located in the outer one-third of the lung.

Exclusion criteria

* Patients requiring lobectomy. * Patients who have not provided written informed consent. * Vulnerable populations.

Design outcomes

Primary

MeasureTime frameDescription
Localization accuracyImmediatedly after Extended Reality (XR)-Assisted CT-Guided LocalizationProcedures in this study will be conducted in a CT room. The accuracy of XR-assisted CT-guided localization will be assessed immediately after localization by employing in-room CT to determine the needle tip position and measure the distance to the target tumor.

Secondary

MeasureTime frameDescription
Assessment of perioperative outcomesThe study assessment time frame from XR-assisted CT-guided localization to discharge is approximately 3 to 7 days.Perioperative outcomes, including intraoperative blood loss, localization time, operative time, and the rate of localization-related complications, will be measured. We will assess whether the incorporation of the localization system leads to reductions in these parameters.

Contacts

CONTACTXu-Heng Chiang
lycansblueray@gmail.com88672655136

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 27, 2026